What question did this study set out to answer?

Evaluate the safety and effectiveness of PF-08634404 in combination with various anticancer agents for advanced solid tumors.

March 19, 2026Open Access

150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)

Puntos clave

Evaluate the safety and effectiveness of PF-08634404 in combination with various anticancer agents for advanced solid tumors.
Phase Ib/II trial design
Testing PF-08634404 with different anticancer agents
Focus on advanced solid tumors, including NSCLC
Promising efficacy observed with PF-08634404 as monotherapy
Manageable safety profile noted in previous Phase II studies
Combination strategies may enhance treatment outcomes in advanced tumors

Resumen

PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as monotherapy and with chemotherapy in 1L non-small cell lung cancer (NSCLC). This study will evaluate PF-08634404 in combination with different anticancer agents in advanced solid tumors including NSCLC.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

E. Felip

Federico Cappuzzo

R. Martins

Journals

ESMO Open

Actions

Institutions

Peking University

Virginia Commonwealth University

Pfizer (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study